Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the
surface of the cornea. Frequently, these pterygia will recur even after surgical resection.
Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of
bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study
is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab
versus pterygium excision alone.